EGFR and non-small cell lung carcinoma: Chin et al reported that prior exposure to platinum agents may reduce the benefit from subsequent treatment with EGFR-TKI for an erlotinib-sensitive EGFR-mutant NSCLC cell via the phosphatidylinositol 3-kinase/AKT survival pathway [12].